Echocardiographic Assessment of Right Ventricular Volumes after
... METHODS This was a single-center, prospective, observational study. The study was approved by the institutional research ethics board. Informed consent was obtained from all participants and/or their legal guardians before enrollment. Patients after TOF repair, aged 8 to 17 years, who were scheduled ...
... METHODS This was a single-center, prospective, observational study. The study was approved by the institutional research ethics board. Informed consent was obtained from all participants and/or their legal guardians before enrollment. Patients after TOF repair, aged 8 to 17 years, who were scheduled ...
Chapter 18: Cardiovascular System (Anatomy)
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
Chapter 18: Cardiovascular System
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
“Do GRACE (Global Registry of Acute Coronary events) risk scores
... From October 2004 to June 2005, all consecutive patients ≥18 years old within 24 hours of the onset of angina at rest and who were hospitalized in any study center were eligible. Patients were included if ACS were finally confirmed during the index hospitalization. Diagnosis of ACS was made if the p ...
... From October 2004 to June 2005, all consecutive patients ≥18 years old within 24 hours of the onset of angina at rest and who were hospitalized in any study center were eligible. Patients were included if ACS were finally confirmed during the index hospitalization. Diagnosis of ACS was made if the p ...
Fast Facts for the Cardiac Surgery Nurse: Caring
... Because of advances in technology over the years, many patients who used to undergo cardiac surgery are now treated in the cardiac catheterization lab. This means that the patients who now have cardiac surgery are often older and sicker than those who had cardiac surgery in the past. Today’s patient ...
... Because of advances in technology over the years, many patients who used to undergo cardiac surgery are now treated in the cardiac catheterization lab. This means that the patients who now have cardiac surgery are often older and sicker than those who had cardiac surgery in the past. Today’s patient ...
Chapter 18: Cardiovascular System (Anatomy)
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
... SV = end diastolic volume (EDV) minus end systolic volume (ESV) EDV = amount of blood collected in a ventricle during diastole ESV = amount of blood remaining in a ventricle after contraction ...
ICD or CRTdevice
... The ICD consists of a generator (box) and a lead or leads. This is implanted under the skin, in the upper area of the chest close to the shoulder. The leads are passed through the veins into the chambers of the heart where they make contact with the muscle. The leads ensure that the ICD can detect e ...
... The ICD consists of a generator (box) and a lead or leads. This is implanted under the skin, in the upper area of the chest close to the shoulder. The leads are passed through the veins into the chambers of the heart where they make contact with the muscle. The leads ensure that the ICD can detect e ...
Document
... Compared to ACS patients who do not have diabetes, those who have diabetes mellitus are at: A. Greater risk of major cardiovascular events and similar risk of major bleeding events B. Greater risk of major cardiovascular events and greater risk of major bleeding events C. Similar risk of major cardi ...
... Compared to ACS patients who do not have diabetes, those who have diabetes mellitus are at: A. Greater risk of major cardiovascular events and similar risk of major bleeding events B. Greater risk of major cardiovascular events and greater risk of major bleeding events C. Similar risk of major cardi ...
Heart rate variability as measurement of heart
... the first is usually based on the computation of the fast Fourier transform (FFT), which is computationally faster, the second requires the estimation of a parametric model (i.e., the estimation of the coefficients of the model), usually an autoregressive model, that depends on additional parameters ...
... the first is usually based on the computation of the fast Fourier transform (FFT), which is computationally faster, the second requires the estimation of a parametric model (i.e., the estimation of the coefficients of the model), usually an autoregressive model, that depends on additional parameters ...
2014 ESC/EACTS Guidelines on myocardial revascularization: web
... without prior functional testing. Invasive coronary angiography has been regarded as the reference standard for the detection and assessment of the severity of CAD. It has better temporal and spatial resolution than MDCT; however, as an invasive procedure, it has higher procedure-related rate of adv ...
... without prior functional testing. Invasive coronary angiography has been regarded as the reference standard for the detection and assessment of the severity of CAD. It has better temporal and spatial resolution than MDCT; however, as an invasive procedure, it has higher procedure-related rate of adv ...
Treatment time and outcome of thrombolytic therapy with strepto
... changing the thrombolytic agent for a guideline recommended fibrin-specific one instead of the currently used streptokinase. This is the trend not only in the developed world but also in India.10 Thrombolysis for reperfusion is recommended up to 12 hours of symptom onset.5,6 In our sample with a med ...
... changing the thrombolytic agent for a guideline recommended fibrin-specific one instead of the currently used streptokinase. This is the trend not only in the developed world but also in India.10 Thrombolysis for reperfusion is recommended up to 12 hours of symptom onset.5,6 In our sample with a med ...
Non-Invasive Transcutaneous Pacing
... Clinicians must not rely solely on the defibrillator’s classification of beats as intrinsic or paced to determine electrical capture. Consider the situation where the patient's intrinsic HR is 62, and the pacer is set at a rate of 60. Since the two rates are very close, pacer spikes and intrinsic be ...
... Clinicians must not rely solely on the defibrillator’s classification of beats as intrinsic or paced to determine electrical capture. Consider the situation where the patient's intrinsic HR is 62, and the pacer is set at a rate of 60. Since the two rates are very close, pacer spikes and intrinsic be ...
Pacemaker potential - Anatomy and Physiology
... • Three differences from skeletal muscle: – ~1% of cells have automaticity ...
... • Three differences from skeletal muscle: – ~1% of cells have automaticity ...
the acute-phase heart rate variability in acute coronary syndrome
... Previously, HRV studies focused on post-MI and chronic heart failure. The decreased DFA alpha is associated with mortality. The acute-phase HRV has not been elucidated. We intended to evaluate acute-phase HRV of acute coronary syndromes (ACS), in comparison with non-ACS subjects. Methods: Our study ...
... Previously, HRV studies focused on post-MI and chronic heart failure. The decreased DFA alpha is associated with mortality. The acute-phase HRV has not been elucidated. We intended to evaluate acute-phase HRV of acute coronary syndromes (ACS), in comparison with non-ACS subjects. Methods: Our study ...
Effectiveness of Implantable Cardioverter Defibrillators for Primary
... and are in NYHA (New York Heart Association) class II or III; patients with nonischemic dilated cardiomyopathy with LVEFs of 35% or less and who are in NYHA class II or III; or patients with left ventricular dysfunction due to previous MI who are at least 40 days post-MI, have an LVEF of 30% or less ...
... and are in NYHA (New York Heart Association) class II or III; patients with nonischemic dilated cardiomyopathy with LVEFs of 35% or less and who are in NYHA class II or III; or patients with left ventricular dysfunction due to previous MI who are at least 40 days post-MI, have an LVEF of 30% or less ...
Coronary Artery Disease
... that lies adjacent to irreversibly damaged myocardium immediately after an infarction despite restoration of coronary blood flow, resolution of pain and ischemic electrocardiographic changes. With time, myocardial contractility to the stunned segment returns to its former function. Shortly after a ...
... that lies adjacent to irreversibly damaged myocardium immediately after an infarction despite restoration of coronary blood flow, resolution of pain and ischemic electrocardiographic changes. With time, myocardial contractility to the stunned segment returns to its former function. Shortly after a ...
Table 2
... changes over time, as in post-MI LV remodeling, end-stage heart failure, heart transplants, cardiotoxic chemotherapy, and timing of valve replacement in valve regurgitation. Contrast should also be considered when LV EF or volumes are used as inclusion or randomization criteria and outcome parameter ...
... changes over time, as in post-MI LV remodeling, end-stage heart failure, heart transplants, cardiotoxic chemotherapy, and timing of valve replacement in valve regurgitation. Contrast should also be considered when LV EF or volumes are used as inclusion or randomization criteria and outcome parameter ...
Nova Scotia Guidelines for Acute Coronary Syndromes
... The definitions for levels of evidence reported in this document are summarized in Appendix A of each document (i.e. the STEMI and NSTEACS guidelines). The levels of evidence are reported where available; if the guidelines offer a different grading for a similar statement, each grading will be liste ...
... The definitions for levels of evidence reported in this document are summarized in Appendix A of each document (i.e. the STEMI and NSTEACS guidelines). The levels of evidence are reported where available; if the guidelines offer a different grading for a similar statement, each grading will be liste ...
Species-specific differences of myosin content in the developing
... Key morphogenetic events during heart ontogenesis are similar in different vertebrate species. We report that in primitive vertebrates, i.e., cartilaginous fishes, both the embryonic and the adult heart show a segmental subdivision similar to that of the embryonic mammalian heart. Early morphogeneti ...
... Key morphogenetic events during heart ontogenesis are similar in different vertebrate species. We report that in primitive vertebrates, i.e., cartilaginous fishes, both the embryonic and the adult heart show a segmental subdivision similar to that of the embryonic mammalian heart. Early morphogeneti ...
Chapter 3 The electrocardiogram
... amount of positive and negative deflection compared with the isoelectric baseline. Having done so, the axis is 90° to this lead, being in either a rightward or leftward direction. For instance, if aVL is the ‘isoelectric’ lead, the direction of the QRS axis is either –120° or +60° (i.e. 90° to the l ...
... amount of positive and negative deflection compared with the isoelectric baseline. Having done so, the axis is 90° to this lead, being in either a rightward or leftward direction. For instance, if aVL is the ‘isoelectric’ lead, the direction of the QRS axis is either –120° or +60° (i.e. 90° to the l ...
Teresa S. Wu, MD, FACEP Director, EM Ultrasound Program
... Remember that cardiac tamponade can develop with as little as 50 mL of fluid accumulating rapidly within the pericardial sac. Chronic pericardial effusions allow for the heart to adjust to the increased pericardial pressures over time, and therefore, patients can have large chronic pericardial effus ...
... Remember that cardiac tamponade can develop with as little as 50 mL of fluid accumulating rapidly within the pericardial sac. Chronic pericardial effusions allow for the heart to adjust to the increased pericardial pressures over time, and therefore, patients can have large chronic pericardial effus ...
IOSR Journal of Sports and Physical Education (IOSR-JSPE) e-ISSN: , p-ISSN:
... M.K.C.G Medical College, Berhampur during the period from 2009-11 after due approval from the institutional ethics committee. For the study healthy young male adults between 17-24 years were included. Cardiac monitor was connected to each subject and Blood Pressure (BP), HeartRate (HR) and Oxygen sa ...
... M.K.C.G Medical College, Berhampur during the period from 2009-11 after due approval from the institutional ethics committee. For the study healthy young male adults between 17-24 years were included. Cardiac monitor was connected to each subject and Blood Pressure (BP), HeartRate (HR) and Oxygen sa ...
Primary Prevention ICD / CRT Task Force Report
... Brugada’s syndrome Patient must be able to give own consent ...
... Brugada’s syndrome Patient must be able to give own consent ...
The Fontan Circulation: The Known, the Unknown and
... right ventricular contraction duration, which is not possible in Fontan patients [15]. No significant improvement in 6 min walking distance was seen in a small group of 10 failing Fontan patients treated with bosentan for 12 weeks. In another small study of eight patients, bosentan showed improvemen ...
... right ventricular contraction duration, which is not possible in Fontan patients [15]. No significant improvement in 6 min walking distance was seen in a small group of 10 failing Fontan patients treated with bosentan for 12 weeks. In another small study of eight patients, bosentan showed improvemen ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.